糖链抗原CA50 IRMA用于消化道恶性肿瘤诊断的价值

• 作 者: 郭子林 刘玉庆 李淑玲 黄爱田
• 机 构: 济宁医学院生物化学教研室
• 出 处: 济宁医学院学报
• 发表日期: 1998年02期
• 关键词: 糖链抗原 CA50 IRMA 恶性肿瘤诊断 肿瘤检测 结肠癌 特异度 免疫放射分析 假阳性 临床诊断 肿瘤标志物

目的探讨糖链抗原ＣＡ５０在消化道恶性肿瘤中的诊断价值。方法利用免疫放射分析方法检测了１６０例血清糖链抗原ＣＡ５０含量，其中正常人２１例，消化道良性疾病５７例，消化道恶性肿瘤８２例。结果显示：正常人组与消化道良性疾病组ＣＡ５０检测值差异不显著（Ｐ＞００５）而各组消化道恶性肿瘤与正常人及良性疾病组相比较有非常显著性差异（Ｐ＜０００１）。消化道各组恶性肿瘤检测的敏感度和特异度分别是：食管癌８５７１％和１００％；胃癌７２７３％和８９４７％；肝癌７７２７％和８３３３％；胰腺癌８８８９％和１００％；结肠癌８７５０％和１００％。结论本文结果表明ＣＡ５０ＩＲＭＡ对消化道恶性肿瘤有较高的临床诊断实用价值。

Objective To investigate the diagnostic value of carbohydrate antigen CA50 in digestive tract malignant tumors. Methods Immunoradiometric assay was used to detect the serum CA50 content of 160 cases of sugar chain antigens, including 21 cases of normal persons, 57 cases of benign gastrointestinal diseases and 82 cases of gastrointestinal malignant tumors. The results showed that there was no significant difference in the CA50 values ​​between the normal group and benign diseases group (P>005), and there was a significant difference between the malignant tumors of the digestive tract and normal and benign disease groups (P<0).  001). The sensitivity and specificity of detection of malignant tumors in various groups of the digestive tract were: esophageal cancer 8571% and 100%; gastric cancer 7273% and 8947%; liver cancer 7727% and 8333%; pancreatic cancer 8889% and 100%; colon cancer 8750% and 100%. Conclusions The results of this study show that CA50IRMA has a high clinical diagnostic value for gastrointestinal cancer.